PMC:7605337 / 4643-5003 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T24","span":{"begin":51,"end":56},"obj":"Body_part"},{"id":"T25","span":{"begin":80,"end":84},"obj":"Body_part"},{"id":"T26","span":{"begin":104,"end":111},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A26","pred":"fma_id","subj":"T26","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"robable that nCOV-2019 uses this receptor on human cells to gain entry into the body.3,6,7,10\nThe spike protein and specifically the RBD in coronaviruses have been a major target for therapeutic antibodies. However, no monoclonal antibodies targeted to RBD have been able to bind efficiently and neutralize nCOV-2019.7,11 The core of nCOV-2019 RBD is a five-st"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T27","span":{"begin":13,"end":22},"obj":"Disease"},{"id":"T28","span":{"begin":334,"end":343},"obj":"Disease"}],"attributes":[{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"robable that nCOV-2019 uses this receptor on human cells to gain entry into the body.3,6,7,10\nThe spike protein and specifically the RBD in coronaviruses have been a major target for therapeutic antibodies. However, no monoclonal antibodies targeted to RBD have been able to bind efficiently and neutralize nCOV-2019.7,11 The core of nCOV-2019 RBD is a five-st"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T48","span":{"begin":45,"end":56},"obj":"http://purl.obolibrary.org/obo/CLO_0053065"},{"id":"T49","span":{"begin":164,"end":165},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T50","span":{"begin":351,"end":352},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"robable that nCOV-2019 uses this receptor on human cells to gain entry into the body.3,6,7,10\nThe spike protein and specifically the RBD in coronaviruses have been a major target for therapeutic antibodies. However, no monoclonal antibodies targeted to RBD have been able to bind efficiently and neutralize nCOV-2019.7,11 The core of nCOV-2019 RBD is a five-st"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T23","span":{"begin":104,"end":111},"obj":"Chemical"}],"attributes":[{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"robable that nCOV-2019 uses this receptor on human cells to gain entry into the body.3,6,7,10\nThe spike protein and specifically the RBD in coronaviruses have been a major target for therapeutic antibodies. However, no monoclonal antibodies targeted to RBD have been able to bind efficiently and neutralize nCOV-2019.7,11 The core of nCOV-2019 RBD is a five-st"}

{"project":"LitCovid-sentences","denotations":[{"id":"T22","span":{"begin":94,"end":206},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"robable that nCOV-2019 uses this receptor on human cells to gain entry into the body.3,6,7,10\nThe spike protein and specifically the RBD in coronaviruses have been a major target for therapeutic antibodies. However, no monoclonal antibodies targeted to RBD have been able to bind efficiently and neutralize nCOV-2019.7,11 The core of nCOV-2019 RBD is a five-st"}

{"project":"LitCovid-PubTator","denotations":[{"id":"128","span":{"begin":13,"end":17},"obj":"Species"},{"id":"129","span":{"begin":45,"end":50},"obj":"Species"},{"id":"146","span":{"begin":98,"end":103},"obj":"Gene"},{"id":"153","span":{"begin":140,"end":153},"obj":"Species"},{"id":"154","span":{"begin":307,"end":311},"obj":"Species"},{"id":"155","span":{"begin":334,"end":338},"obj":"Species"}],"attributes":[{"id":"A128","pred":"tao:has_database_id","subj":"128","obj":"Tax:2697049"},{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"Tax:9606"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Gene:43740568"},{"id":"A153","pred":"tao:has_database_id","subj":"153","obj":"Tax:11118"},{"id":"A154","pred":"tao:has_database_id","subj":"154","obj":"Tax:2697049"},{"id":"A155","pred":"tao:has_database_id","subj":"155","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"robable that nCOV-2019 uses this receptor on human cells to gain entry into the body.3,6,7,10\nThe spike protein and specifically the RBD in coronaviruses have been a major target for therapeutic antibodies. However, no monoclonal antibodies targeted to RBD have been able to bind efficiently and neutralize nCOV-2019.7,11 The core of nCOV-2019 RBD is a five-st"}